

Unintentional Weight Loss in Long Term Care Residents with Alzheimer's Disease and Weight Response with the Use of Docosahexaenoic Acid (DHA)/ Eicosapentaenoic Acid (EPA) and Bioflavonoids: A Case Series

Mario Cornacchione DO MS CMD FAAFP, Clinical Associate Professor, Department of Family Medicine, The Commonwealth Medical College, Scranton, PA
Director, Northeast Pennsylvania Memory & Alzheimer's Center
Geriatric Research & Consulting Group LLC

INTRODUCTION

Cachexia/dehydration may be the immediate cause of death in the end stage of dementia in as many as 35% of nursing home residents.⁸ Cachexia is associated with suppressed appetite, food intake and body weight while proinflammatory cytokines are increased.⁹ Proinflammatory cytokines directly result in feeding suppression and lower intake of nutrients and cachexia is nearly always accompanied by anorexia. IL-1 beta and tumor necrosis factor alpha (TNF α) act on the glucose-sensitive neurons in the satiety and hunger sites in the hypothalamus.¹⁰

An association between high levels of circulating TNF α and unexplained weight loss in AD has been shown.¹³ Serum TNF α has been shown to be lower in mild-moderate Alzheimer's disease (AD) compared to severe AD.¹² The levels of TNF α , IL-1beta, IL 6, and IL10 were elevated in the serum of patients with dementia.^{14, 15, 18} A minority of studies have shown no significant differences between AD subjects and controls in the mean serum levels of TNF α and other cytokines.¹⁷ Brain synthesis of cytokines has been shown in peripheral models of cancer, peripheral inflammation, and during peripheral cytokine administration¹¹ and strikingly increased CSF levels of TNF α have been demonstrated in AD.¹⁶

METHODS

Two residents in one facility, cared for by the investigator, in a moderate stage of dementia with 10% or greater weight loss over the previous six months despite the usual interventions at the facility (the addition of fortified foods, 2 Cal Supplement[®] bid, offering snack tid, and 1 on 1 assistance with meals in a small dining room setting) were chosen. A TSH, CBC, complete metabolic profile, urinalysis, physical examination, medication review and Cornell Scale for Depression in Dementia (CSDD) were performed during the 6 month period. Both residents were on an acetylcholinesterase inhibitor (ACHE) and had a 10 day washout prior to intervention.

After informed consent was obtained from the family of each resident, 570 mg DHA and 870 mg EPA plus 225 mg of bioflavonoid per day were administered. A proprietary formulation of bioflavonoids, OPC-3[®] was used. OPC-3 consists of an isotonic formulation of well studied flavonoids derived from extracts of bilberries, citrus fruit, French maritime pine bark (Pycnogenol), red wine (resveratrol), and grape seeds. The usual interventions were continued. Weights were followed over the 6 month period following the intervention.

RESULTS

Resident 1: 92 y.o. diagnoses: Alzheimer's disease, depression, hypothyroidism, hypertension, diabetes II, hyperlipidemia. Medications: donepezil 10 mg, memantine 10 mg bid, levothyroxine, citalopram 10 mg, KCl, multivitamin. MMSE 14, 50-80% meals consumed, weight loss 1% over 1 month and 11% over 6 months immediately prior to intervention.

Resident 2: 94 y.o., diagnoses: Alzheimer's disease, COPD, Oseteoarthritis. Medications: donepezil 10 mg, memantine 10 mg bid, vitamin D 800 IU, multivitamin, Ca carbonate 1000mg. Failed trial of mirtazapine 15 mg daily for weight loss. Hospice care during the last 3 months of weight loss prior to intervention and throughout the intervention period. MMSE 13, 0-50% meals consumed, weight loss 3.7% over 1 month and 10% over 6 months immediately prior to intervention.

Post intervention total percent weight change (Fig. 1): 1, 3 and 6 months respectively for Resident 1 were +0.9%, +5.1%, +6.9% and for Resident 2 were 0%, +1%, -1%. Both residents showed an improvement in appetite and general increase in percent of meals eaten. At request of Resident 2's family the intervention was stopped at 6 months but restarted 1 month later due to a 6% weight loss. Subsequent total weight gain was 3% at 1 month and 5.1% at 2 months. Weight change in pounds (Fig. 2-Resident 1, Fig.3-Resident 2)

*Laboratory work, CSDD, physical examination unremarkable and no change in appetite with the 10 day ACHE washout in both residents (ACHE restarted after washout).

Fig. 1 Percent Weight Change Pre/Post Intervention (DHA/EPA + Bioflavonoids)




Fig. 2 Weight Change Pre/Post Intervention (DHA/EPA + Bioflavonoids)





Fig. 3 Weight Change Pre/Post Intervention (DHA/EPA + Bioflavonoids)



DISCUSSION/CONCLUSION

The importance of ingesting foods and supplements high in antioxidants is becoming more valued as oxidative stress from reactive oxygen species is being uncovered as a common pathologic mechanism to inflammatory states by the induction of proinflammatory cytokines.⁴

In recent years, the constituents in fruits and vegetables predominantly responsible for their health benefits have been identified as bioflavonoids which are anti-inflammatory. Reductions of plasma oxidative stress status by 10.1% and plasma C-reactive protein by 52.1% have been demonstrated with OPC-3 use.⁵ Adequate dietary intake of omega-3 polyunsaturated fatty acids increases tissue concentrations of EPA and DHA that reduce proinflammatory cytokine production^{1,2} and downregulate inflammation.^{3, 19, 20}

Although this was an uncontrolled intervention, resident 1 showed clinically meaningful weight gain through the entire 6 month observation period and resident 2 showed stabilization of weight loss within 30 days of the intervention with continued weight maintenance throughout the 6 month observation period. Resident 1 also showed weight loss when the intervention was discontinued and clinically meaningful weight gain when restarted.

CONCLUSION

Given the evidence in the literature supporting a mechanism for these nutritional interventions with our observed improvement in weight and appetite, further study in a controlled setting is warranted.

REFERENCES

1. Donnelly CL. Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process. *Am J Clin Nutr* 2008;90:445S-455S.
2. Bales KR, Menniger and mediator interactions among lipids, acetylcholine, and dopamine. *Am J Clin Nutr* 1993;57(suppl):795S-805S.
3. Nutritional modulation of inflammation by polyunsaturated fatty acids. *Am J Clin Nutr* 2008;88(suppl):1400S-1405S.
4. Nutrition and neurodegeneration: Principles and practice. *Trends Neurosci* 2000;23:14-22.
5. Hall J, Liu QH, Tan EC. Tocopherol Oxidation stress induced in participants: An act of antioxidant. *Biochem Pharmacol* 2008;76:100-107.
6. Cornacchione M, Cornacchione A, Smith S, Scholten F, Wilmer J, Blumenthal J. Improvement in Circulation and Cardiovascular Risk Factors With a Proprietary Supplement of Flavonoid OPC-3. *Am J Geriatr Pharmacol* 2008;2:184-194.
7. Olan L, Laitinen J. The role of polyunsaturated fatty acids in protection against dementia. *Int J Geriatr Psychiatry* 2007;22:1083-1093.
8. Zou Y, Fennell C, Cornacchione M, et al. Cognitive impairment and malnutrition affect quality of life and functional status in nursing home residents with dementia. *Am J Geriatr Psychiatry* 2007;15:101-107.
9. Cornacchione M, Cornacchione A, Smith S, Scholten F, Wilmer J, Blumenthal J. Impact of dementia on quality of life and functional status in nursing home residents. *Am J Geriatr Psychiatry* 2007;15:101-107.
10. Thomas DR. Role of animal models in aging: examining the relationship of dementia, sarcopenia and cachexia. *Clin Nutr* 2007;26(suppl):188S-192S.
11. Cornacchione M, Cornacchione A, Scholten F, Wilmer J, Blumenthal J. Calcium mediated alterations in liver metabolism promote functional decline in cardiac output patients. *J Surg Res* 2008;144:177-182.
12. Cornacchione M, Cornacchione A, Scholten F, Wilmer J, Blumenthal J. Calcium mediated alterations in liver metabolism promote functional decline in cardiac output patients. *J Surg Res* 2008;144:177-182.
13. Paganoni A, Di Rosa A, Paganoni L, Spasiani F, Spasiani F, Paganoni B, Neri C, Paganoni C, Di Giambardino M, Alessi G. Proinflammatory cytokines in acute and chronic cachexia: correlation with in vivo muscle mass and higher levels of interleukin-6 in cachectic disease patients. *Eur J Clin Invest* 2004;34:1020-1026.
14. Cornacchione M, Cornacchione A, Scholten F, Wilmer J, Blumenthal J. Relationship between weight loss and circulating cytokines in patients with Alzheimer's disease. *Thromb Haemostas* 2007;87:1612-1614.
15. Angelopoulos T, Angelopoulos I, Vagstad H, Skjellum I, Dierker K, Costa V, Balogh Z. Cytokines in Alzheimer's disease and vascular dementia. *Int J Geriatr Psychiatry* 2008;23:1005-1012.
16. Cornacchione M, Cornacchione A, Scholten F, Wilmer J, Blumenthal J. Relationship between weight loss and circulating cytokines in patients with Alzheimer's disease. *Thromb Haemostas* 2007;87:1612-1614.
17. Cornacchione M, Cornacchione A, Scholten F, Wilmer J, Blumenthal J. Relationship between weight loss and circulating cytokines in patients with Alzheimer's disease. *Thromb Haemostas* 2007;87:1612-1614.
18. Cornacchione M, Cornacchione A, Scholten F, Wilmer J, Blumenthal J. Relationship between weight loss and circulating cytokines in patients with Alzheimer's disease. *Thromb Haemostas* 2007;87:1612-1614.
19. Cornacchione M, Cornacchione A, Scholten F, Wilmer J, Blumenthal J. Relationship between weight loss and circulating cytokines in patients with Alzheimer's disease. *Thromb Haemostas* 2007;87:1612-1614.
20. Cornacchione M, Cornacchione A, Scholten F, Wilmer J, Blumenthal J. Relationship between weight loss and circulating cytokines in patients with Alzheimer's disease. *Thromb Haemostas* 2007;87:1612-1614.